Skip to main content
. 2021 Apr 22;13:17588359211006950. doi: 10.1177/17588359211006950

Figure 2.

Figure 2.

The flow chart of guiding clinical application of immune checkpoint blockade therapy for KRAS-mutant lung adenocarcinomas in combination with TP53 and LKB1.

CT, chemotherapy; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; NGS, next-generation sequencing; PD-L1, programmed death-l.